BCR and chronic myelogenous leukemia, BCR-ABL1 positive: At present, BCR/ABL fusion gene can serve as biomarker for monitoring disease transition from a chronic phase to acute stages and the presence of remaining leukemic cells during and after treatment in CML patients5.